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ABSTRACT
Background:

Traditional

methods for detecting positive blood cultures include the usc of

broth bottles with sensitive indicators for growth. These techniques

can take 24-48 hours

to signal a positive test. Another 24 hours arc often required to determine the species of
the organism.
infections

The use of rapid diagnostic

testing for Candida species bloodstream

provides accurate species identification

Objective:

Evaluate the time to appropriate

diagnostic

testing was utilized.

Methods:

This study was a retrospective,

in less than two hours.

antifungal therapy in patients in which rapid

observational

cohort of patients who had

positive blood cultures for Candida species and had rNA FISH@ technology
rapid diagnostic
Memorial

test. Patients admitted to either Sidney & Lois Eskenazi or Wishard

Hospital during the time frame of January 1,2012 to November

eligible for inclusion.

and mortality.

30,2014

were

Patients had to have at least one positive blood culture for Calldida

species. The following data was collected: demographics,
antimicrobial

used as a

regimen, time to appropriate

antimicrobial

microbiologic

data,

therapy, hospital length of stay

Results: Of the 27 blood cultures in which PNA FISH® technology was used, the
antifungal therapy was 15.24 ± 17.7 hours. Therapy was

average time to appropriate
appropriately

initiated or adjusted after the PNA FISH® results in 330;;) of patients (9/27).

The mean hospital length of stay was 24.4 ± 18.8 days and the mean intensive care unit
(lCU) length of stay was 15 ± 20.7 days. All-cause mortality was 22.2°;;) (6/27).

Conclusion:

This study showed that the average time to appropriate

15.24 hours was comparable

to current published studies. Due to the small number of

patients in which therapy was appropriately
beneficial

to educate healthcare

how this technology

antifungal therapy of

adjusted after the PNA FISH®, it may be

providers about the usefulness of the PNA FISH(!y and

may be utilized to enhance clinical practice and potentially

improve

patient outcomes.

BACKGROUND
Candidemia
infections

is the fourth most common cause of nosocomial

bloodstream

in the United States. Candida species are the most common cause of invasive

fungal infections

in humans.'

Common risk factors for candidemia

venous catheters, parenteral nutrition, renal replacement
agents and broad-spectrum

include: central

therapy, immunosuppressive

antibiotic use. Invasive candidiasis

has an estimated mortality

01'47%.'
Traditional

methods for detecting positive blood cultures for an organism include

the use of broth bottles with sensitive indicators for growth. These techniques can take
24-48 hours to indicate a positive result. Then, an additional 24 hours is often required to
determine

the species of the organism. One can then expect another 24 hours for

2

antimicrobial

susceptibility

species bloodstream
antimicrobial
Examples

testing.2 The use of rapid diagnostic testing for Candida

infections may significantly

reduce the time to appropriate

therapy by providing correct species identification

of rapid diagnostic

PCR (BD GeneOhm

in less than two hours.

tests currently available include: PNA FISH (AdvanDx),

and Cepheid) and MALDI-TOF

(Bruker Daltonics Inc.j'

The Yeast Traffic Light@ PNA FISH@ (AdvanDx,

Woburn, MA) provides rapid

identification

of five different Candida species. This technology

hybridization

(FISH) method which uses PNA probes to hybridize to specific ribosomal

RNA sequences

is a fluorescence

in situ

of C. albicans, C. parapsilosis, C. tropicalis, C. glabrata and C. krusci.

This test provides identification

of C. a/Means and/or C. parapsilosis, C. glabrata and/or

C. krusei and C. tropiealis from positive blood culture smears by signaling a different
color for each organism under fluorescence

microscope

C. parapsilosis will be signaled by a green-positive,
signal as a red-positive

examination.

C. glabrata and/or C. krusei will

and C. tropiealis will signal as a yellow-positive.

positive result is approximately

Woburn, MA) is distributed as

a fixation solution, a yeast traffic light PNA, a 60x wash solution and a

medium. The test is performed

rhodamine-labeled

of the

microscope.

The Yeast Traffic Light@ PNA FISH@ (AdvanDx,

mounting

The time to a

90 minutes." Figure I is a sample interpretation

results of the assay using a fluorescence

a kit containing

C. albicans and/or

by combining a mixture of fluorescein and

PNA probes to a blood smear. Hybridization

minutes at 55° C which is followed by a post-hybridization

is performed

for 30

wash with the wash solution.

It is then prepared onto the mounting medium and able to be examined via fluorescence
.

1

microscopy ..

3

Limitations

of this test include the inability to differentiate

between C. albicans or

C. parapsilosis and C. glahrata or C. krusei. The test also cannot differentiate

Candida

species in cultures with mixed growth. The assay requires further isolation on solid
growth media to detel111ine correct species identification.
includes a potential false-positive

An additional limitation

result that may occur due to the sequence similarity of

C. glabrata to C. nivaricnsis and C. bracarensis, which may lead to a t~dse-positive (red).
A false-positive
their similarity

(green) may also occur with C. orthopsilosis and C. metapsilosis due to
to C. parapsilosis.3 Finally, the assay does not provide susceptibility

information.
limit for all five Candida species has been determined

The detection
approximately

to be

105 cfu/mL by serial dilutions of positive cultures which is consistent with

traditional

staining techniques.

containing

Candida species were all proven to show the correct organism to be isolated.

Reproducibility

Specificity testing on 75 laboratory and reference cultures

testing of 19 isolates showed 98.7<% total agreement across three
3

different testing sites.

Hall and colleagues

performed

a study on 216 blood cultures positive for Calldida

species." Of these cultures, the Yeast Traffic Light@ rNA FISH@ identified the correct

Candida species 96% of the time (207/216). Using a 30-minute hybridization
Yeast Traffic Light@ rNA FISH@ correctly identified

time, the

100% of C. albicans (39/39), 94%

of C. parapsilosis (31/33), 100<%of C. glahrata (34/34), 100<Yoof C. krusei (24/24) and
94% of C. tropicalls (3 1/33). They found equivalent results using a 90-minute
hybridization

time.4 Although there is an abundance

of data regarding the specificity and

4

sensitivity of the PNA FISH® assay, the clinical application has only been briefly
examined in recent years.
Heil and colleagues compared time to targeted therapy, hospital length of stay and
in-hospital

mortality before the implementation

They calculated

a statistically

signiticant

of the rNA FISH® technology and after.

shorter mean time to targeted therapy with the

PNA FISH® of 0.6 day or 14.4 hours compared to 2.3 days with traditional techniques
(p=O. 0016). Hei I and co IIeagues found no stati sticall y si gni fican t difference in hospi ta I
length of stay or in-hospital mortality between the two groups."
Aitken and colleagues found the average time to identification of yeast by
traditional

laboratory

methods to be 2.2 ± 1.3 days. The authors then performed a 5,000

person Monte Carlo simulation,
antifungal

in which they found that the average time to initiation of

therapy was 3.5 ± 2.1 days with traditional methods as compared

to 2.6 ± 1.3

6

days with the PNA FISHcID.

NEED FOR THE STUDY
The current Infectious Disease Society of America guidelines for the management
of candidiasis recommend initial selection of antifungal therapy based on species
identification,

making species identification

key for clinical decision making.'

patients are not initiated on an antifungal until yeast identification
Appropriate
is identified.'

pathogen-specific

Most

after a Gram stain.

therapy is generally not initiated until the Candida species

The rNA FISH@ may serve as a reliable tool to determine speciation

within 90 minutes which is much faster than traditional methods of detection which can

take three to five days.

5

One disadvantage
approximately

of the PNA FrSH® is cost. The equipment cost is
8

$1,000 and $30-$80 is required per test. This raises the question of

whether the cost is worth the potential outcome. A goal of the current study was to
determine

the effect of the rNA FISl-ICJ.D
on time to appropriate

appropriate

therapy modification

antifungal therapy,

and the impact on overall clinical outcomes for patients.

Limited literature is currently available regarding the use of PNA FISH® for
candidemia

and subsequent

clinical outcomes. Therefore,

effect of rNA FISH® technology

on time to appropriate

it is beneficial to explore the
antifungal therapy, hospital

length of stay and mortality.

OBJECTIVE
The primary objective in this study was to determine the time to appropriate
antifungal

therapy in patients with Candida species bloodstream

infections in which the

PNA FrSH® assay was utilized.
Secondary

objectives

therapy was appropriately

include: the percent of patients in which antimicrobial

adjusted after the PNA FISH@ results, total hospital length of

stay, intensive care unit length of stay and all-cause mortality.

METHODS
Study Design: This study was a retrospective,

observational

cohort of patients with

positive blood cultures for Candida species and had rNA rISH@ technology
rapid diagnostic

test on the blood culture specimens.

status from the Indiana University

Institutional

used as a

This study received exemption

Review Board.
6

The process for detennining
Eskenazi

final Candida speciation for positive blood cultures at

Health is as follows: After a positive Gram stain for yeast is identified from a

blood culture, the rNA FISH® is perfomled by the laboratory. These results are then
reported to the physician.

The final step in the process is to complete standardized

testing

to obtain final speciation using the VITEK2 system.

Inclusion Criteria: Patients admitted to either Sidney & Lois Eskenazi or Wishard
Memorial

Hospital during the time frame of January 1,2012 to November 30,2014

were

eligible for inclusion. Patients had to have at least one positive blood culture for Candida
species. If patients had multiple positive cultures for the same Candida species during the
same admission,

only the first positive culture was included.

Exclusion Criteria: Patients were excluded if they did not have the PNA FISH(IDrapid
diagnostic

test used on their blood culture. Patients who were younger than 18 years of

age, pregnant or prisoners were also excluded.

Data Source: Data was extracted from electronic medical records of eligible patients
admitted to Sidney & Lois Eskenazi Hospital or Wishard Memorial Hospital during the
time frame of January

1,2012 to November

30,2014.

The data collected included: age,

gender, allergies, past medical history, location of the blood draw, hospital length of stay,

leu length
antifungal

of stay, microbiologic

data, antimicrobial

regimen details, time to appropriate

therapy and all-cause mortality during hospital admission.

Definition ojAppropriate Ant(jllflga/ Therapy: In accordance with the Infectious Disease
Society of America's
appropriate

antifungal

clinical practice guidelines

for the treatment of candidiasis,

therapy for C. ntbicans, C. parapsi/osis.

and C. tropiea/is was
7

defined as fluconazole

antifungal therapy for C. glabrata and C. krusei

and appropriate

was defined as an echinocandin

I

(the formulary option being caspofungin

Health). If the patient was started on appropriate
on susceptibilities,

time to appropriate

at Eskenazi

empiric therapy then de-escalated

therapy was then based on appropriate

based

empiric

therapy.

Statistical Ana~vsis: Descriptive statistics were utilized for the primary and secondary
objectives

of this study.

RESULTS
A total of 52 blood cultures in 52 patients which were positive for Candida
species were evaluated.
technology

Of these, 25 blood cultures were excluded because rNA FISH@

was not used to analyze the blood culture. This left a sample of 27 blood

cultures positive for Candida species in which rNA FISH@ technology
I outlines patient demographic

was used. Table

information.

Figure 2 shows the number of different Candida species identified by the rNA
FISH® compared

to the final speciation results. The species determined

by the rNA

FISH® were consistent with the final speciation results 100% of the time (27/27).
Susceptibility

testing for every Candida species blood cultures is not routine practice at

Eskenazi Health, however, susceptibility

testing was performed on seven of the positive

cultures: five C. glabrata isolates, one C. krusei isolate and one C. parapsi!osis isolate.

The average time to appropriate

anti fungal therapy was 15.24 ± 17.7 hours. The

mean hospital length of stay was 24.4 ± 18.8 days. Twenty-three

of 27 patients (8YYt»)

were admitted to the leu during their hospital stay, while four patients stayed on the

7

general medical units. Of the K'U patients, the mean leU length of stay was 15 ± 20.
days. All-cause
objectives.

mortality was 22.2% (6/27). Table 2 outlines the primary and secondary

Out of the 27 included blood cultures, the infectious diseases consult service

was formally consulted and had documented
cultures. The recommendations

recommendations

in 24/27 of the positive

were accepted in all 24 cases in which the infectious

diseases consult service was consulted.
Appropriate

empiric therapy was started in 92.6(10 of positive blood cultures

(25/27). Therapy was initiated or changed after the rNA FISH@ for 33°;;) of positive
blood cultures (9/27). Table 3 outlines the timing of antifungal therapy initiation and
Table 4 describes the antifungal

therapy regimens by Candida species in all 27 positive

blood cultures.

DISCUSSION
Heil and colleagues

evaluated the PNA FISH® assay and its impact on the

treatment of Candida species bloodstream
species identification,

5

infections.

The study evaluated the time to

time to targeted therapy, clinical outcomes (culture clearance,

hospital length of stay and hospital mortality) and the cost effectiveness
FISH® before and after test implementation.

The results found a statistically

decrease in time to targeted therapy after implementation
implementation
compared

of the rNA
significant

of PNA FISI-ICID.In the pre-

of the rNA FISH® group, time to targeted therapy was 2.3 days

to 0.6 day (14.4 hours) in the post_implementation

(p=O.OO 16).5 These findings are comparable
time to appropriate

of the rNA FISI-{(R)group

to the enrrent study findings for average

antifungal therapy of 15.24 ± 17.7 hours.
9

The study done by Heil and colleagues

found no statistically significant difference

in hospital length of stay between the pre-implementation
implementation
statistically

group and the post-

group (25 days versus 12 days; p==0.82). This study also found no

significant

difference

the post_implementation

in mortality between the pre_implementation
5

group (19% versus 5%; p>0.99).

group and

Hospital length of stay was

much longer in the current study compared to the study done by Heil and colleagues.
terms of mortality, the current study is comparable
colleagues

(19% compared

In

to the study done by Heil and

to 22.2%) with the current study's measure of all-cause

mortality being slightly higher.
Aitken and colleagues
technologies

in antifungal

proven eandidemia.

performed a study to assess the role of rapid diagnostic

stewardship.6

The researchers

The study included 162 patients with culture

evaluated the time to initiation of therapy and tound

the average to be 3.5 ± 2.1 days. Using this data they compared their findings to a 5,000
person Monte Carlo simulation.

They found that the average time to initiation of therapy

was 2.6 ± 1.3 days with the rNA FISH®.6 The average time to initiation of therapy was
much higher than what was found in the current study (2.6 ± 1.3 days compared to 15.24

± 17.7 hours).

The cun-ent study had multiple limitations including retrospective

design, small

sample size and being a single center study. In 2012, a change was made in the reporting
strategy for positive cultures by removing the wording "by rNA FISHC({J"as it was
believed the statement may lead to misinterpretation

of the results. This may have

resulted in exclusion of cultures in which the rNA FISH@ was used. The authors
assumed the rNA FISH(I{)was used if the medical record notes indicated C. albtcans
10

and/or C. parapsilosis or C. glabrata and/or C. krusel. There were multiple potential
inconsistencies

in result reporting as provided by the medical records.

CONCLUSIONS
In conclusion,

this study found an average time to appropriate

17.7 hours in patients in which PNA FISH® technology
test for Candida species bloodstream

was used as a rapid diagnostic

infections. This result is comparable

of a study done by Heil and colleagues,

to the results

in which the average time to targeted antifungal

therapy after PNA FlSH® implementation
It would be beneficial

therapy of 15.24 ±

was 14.4 hours.

in the future to evaluate the time to appropriate

therapy before and after PNA FISH@ implementation.

This would provide the ability to

run data analyses and determine statistical significance,
being able to evaluate descriptive

antifungal

as this study was limited by only

statistics.

This study found that only 33°/cl of positive blood cultures had therapy changed or
initiated after the PNA FrSH@ results were reported to the physician. This shows a
possible area for improvement

in patient care. Educational efforts should be expanded to

health care providers to provide infoffilation on the use of the rNA FISH® as a rapid
diagnostic

test. This may improve time to appropriate

in which species identification

is key in determining

therapy in patients with candidemia
appropriate

antifungal therapy.
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Table 1: Patient Demographics
n=27
Age (years)"

57.15 (16.9)

Maleb

19 (70.4)

Primary teamb

Medical: 20 (74)
Surgical: 5 (19)
Other: 2 (7)

a

=

data reported as average (± SD)

b = data reported as n (%)

13

Table 2: Primary and Secondary Objective Outcomes
n=27
Time to appropriate
Appropriate

therapy (hours)"

therapy after PNA FISH®b

Not appropriate

therapy after PNA FISH®l)

Hospital length of stay (days)"

24.4 (18.8)

6

mortality"

= data reported as average

I (3.7)

15 (20.7)

ICU length of stay (days)"

a

9 (33)

23 (85.2)

ICU admissiol~h

All-cause

15.24(17.7)

(22.2)

(± SD)

b = data reported as n (%)
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Table 3: Timing of Antifungal

Therapy Initiation

1

n=27

Therapy changed or initiated after rNA FISH(f~a

7 (26)

Therapy started after final speciation"
a

Therapy started before physician notification
a

No physician notification

9 (33)

7 (26)

4 (15)

a= data reported as n (%)

15

Table 4: Empiric and Final Antifungal

Therapv

Species

Empiric Therapy

Final Therapy

n (%)

c. albicans

Fluconazole

Fluconazole

7 (26)

C. glabrata

Caspofungin

Caspofungin

6 (22)

Caspofungin

Voriconazole

3 (11)

Caspofungin

Fluconazole

1 (3.7)

Fluconazole

Caspofungin

I (3.7)

None

None

1 (3.7)

Voriconazole

Voriconazole

I (3.7)

C. krusei

Fluconazole

Fluconazole

4 (15)

C. parapsilosts

Caspofungin

Fluconazole

2 (7.5)

Fluconazole

Fluconazole

1 (3.7)

C. tropicalis

16

Figure 1.

C. albicans (top left), C. tropicalis (top middle), C glabrata (top right), mixed positive
(bottom left) and negative (bottom middle) adapted from:
Yeast Traffic Light@ PNA FISH@ [package insert]. Woburn, MA: AdvanDx; 2011.
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Figure 2: Species Identification

Species Identification
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